Tıp Fakültesi / Faculty of Medicine

Permanent URI for this collectionhttps://hdl.handle.net/11727/1403

Browse

Filters

2016 - 20172

Settings

Author: search.filters.author.Akkaya, BaharHas files: No

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    C-MYC and BCL2 Translocation Frequency in Diffuse Large B-Cell Lymphomas: A Study Of 97 Patients
    (2016) Akkaya, Bahar; Salim, Ozan; Akkaya, Hampar; Ozcan, Mualla; Yucel, Orhan Kemal; Erdem, Ramazan; Iltar, Utku; Undar, Levent; https://orcid.org/0000-0002-7070-6901; 26960633; ABG-2028-2020
    Purpose: Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma with marked biologic heterogeneity. MYC and BCL2 rearrangements have been reported in a proportion of DLBCLs, where they may be associated with an adverse clinical outcome. The aim of this study was to determine the frequency of MYC and BCL2 translocations in DLBCL and assess the prognostic impact in DLBCL patients. Materials and Methods: HAIR SPACE In the present study, we evaluated the expression patterns of CD 10, BCL6, and MUM 1 by immunohistochemistry in 121 cases with DLBCL in tissue microarray (TMA): 62 cases in germinal center B-cells (GCBs); and 59 cases in activated B-cells (ABCs) of which 60 were females and 61 were males. MYC and BCL2 rearrangements were investigated by interphase fluorescence in situ hybridization on TMAs in 97 DLBCLs. Result: MYC rearrangements were observed in 11 of 97 cases. There was no association with other clinical features, including age, sex, and nodal/extranodal disease. MYC rearrangement was associated with significantly worse overall survival (P < 0.01). BCL2 rearrangements were observed in 14 of 97 cases. There was no association with other clinical features including age and sex. BCL2 rearrangement had a worse outcome (P < 0.01). MYC and BCL2 rearrangements were observed in 3 of 97 cases with the age ofHAIR SPACE 53 (female), 53, 63 years old, respectively, died in 24, 18, and 35 months after the diagnosis. Two cases had primary nodal and one case primary extranodal presentations. All these patients had stage IV disease. Conclusion: We concluded that C-MYC and BCL2 may contribute to aggressive transformation, and more mechanism-based therapy should be explored. Targeted therapies involving these rearrangements and its associated pathways may change the fate of DLBCLs. Analysis of MYC gene rearrangement along with BCL2 is critical in the identification of high-risk patients with poor prognosis.
  • No Thumbnail Available
    Item
    Changes in Expressions of ADAM9, 10, and 17 As Well as Alpha-Secretase Activity in Renal Cell Carcinoma
    (2017) Erin, Nuray; Ipekci, Tumay; Akkaya, Bahar; Ozbudak, Irem Hicran; Baykara, Mehmet; https://orcid.org/0000-0002-2755-0526; https://orcid.org/0000-0001-6687-1587; 27692848; AAB-2986-2020; C-4815-2016
    Background: ADAM9, 10, and 17 are a class of disintegrins and metallproteinases with oc-secretase activity. There are conflicting results regarding the role(s) of ADAM9, 10, and 17 in carcinogenesis, and only a few studies have examined their levels and cellular localization in renal cell carcinoma (RCC). Studies examining changes in oc-secretase activity in RCC compared to enzymatic activity of the uninvolved kidney are lacking. Method: A cross-sectional study was conducted in 56 patients undergoing radical nephrectomy after the diagnosis of RCC. alpha-Secretase activity was determined using flourogenic substrate in freshly frozen tumor tissues as well as similarly treated tissues from the neighboring kidney. Immunohistochemical analyses of ADAM9, 10, and 17 were also performed. Results: alpha-Secretase activity decreased markedly in all types of RCC as compared to neighboring uninvolved kidney tissue having 5 to 10 times higher levels of oc-secretase activity. Although type-dependent variations were observed, tumoral expressions of ADAMs, except for ADAM17, were lower in the tumors compared to that of neighboring tissues, but the changes in oc-secretase activity were greater. In RCC tissue, ADAM9 expressions were localized in nuclear and cytoplasmic compartments, whereas ADAM10 and 17 were present predominately in the cytoplasm potentially explaining the markedly decreased enzyme activity. Membranous localization of ADAMs was noted in uninvolved kidney tissue. Conclusions: The loss of alpha-secretase activity observed here in conjunction with previous findings argue against tumorigenic effects of ADAM9, 10, and 17 supporting that increased nuclear and cytoplasmic expression may be an attempt to compensate for loss of function. (C) 2017 Elsevier Inc. All rights reserved.